Cellectis S.A. (NASDAQ:CLLS) tinted gains of +0.97% (+0.18 points) to US$18.76. The volume of 0.12 Million shares climbed down over an trading activity of 150.12 Million shares. EPS ratio determined by looking at last 12 month figures is -2.11. Over the same time span, the stock marked US$38.85 as its best level and the lowest price reached was US$15.44. The corporation has a market cap of US$756.97 Million.
Cellectis S.A. (NASDAQ:CLLS)’s earnings per share has been growing at a -36.4 percent rate over the past 5 year when average revenue increase was noted as 15.5 percent. The return on equity ratio or ROE stands at -23 percent while most common profitability ratio return on investment (ROI) was -35 percent. The company’s institutional ownership is monitored at 29.5 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 4 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 2 think it is Hold. Recently, analysts have updated the overall rating to 1.75. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Grand Canyon Education, Inc. (NASDAQ:LOPE) is worth US$4.53 Billion and has recently risen 0.97% to US$94.91. The latest exchange of 0.4 Million shares is below its average trading activity of 398.52 Million shares. The day began at US$93.72 but the price moved to US$93.36 at one point during the trading and finally capitulating to a session high of US$95.09. The stock tapped a 52-week high of US$130.1 while the mean 12-month price target for the shares is US$140.5.
Currently, the stock carries a price to earnings ratio of 21.75, a price to book ratio of 3.98, and a price to sales ratio of 4.82. For the past 5 years, the company’s revenue has grown 13.8%, while the company’s earnings per share has grown 21.1%. With an institutional ownership near 99.7%, it carries an earnings per share ratio of 4.36.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 3 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.75.